Key Dates

Related Announcements

RFA-NS-22-038 - Research Program Award (R35 Clinical Trial Optional)

NOT-NS-23-023 - Notice of Change to Eligibility Information for RFA-NS-22-038 "Research Program Award (R35 Clinical Trial Optional)" (RESCINDED)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to inform applicants of a correction to the Eligibility Information for RFA-NS-22-038 "Research Program Award (R35 Clinical Trial Optional)". As stated in section I of the Funding Opportunity Announcement (FOA), to mitigate against a lapse in funding, a PD/PI may submit an NINDS application of scientifically overlapping scope in parallel with the RPA application with the understanding that if both applications are judged to be meritorious and considered for funding, only one of the awards could be accepted. Language in section III. Eligibility Information, regarding not accepting duplicate or highly overlapping applications has been removed to be consistent with the language in section I. Changes to the FOA are shown below. Additionally, this notice rescinds NOT-NS-23-023 Notice of Change to Eligibility Information for RFA-NS-22-038 "Research Program Award (R35 Clinical Trial Optional)".

Currently Reads:

Section III. Eligibility Information

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Modified to Read:

Section III. Eligibility Information

3. Additional Information on Eligibility

Number of Applications

A PD/PI may submit an NINDS application of scientifically overlapping scope in parallel with the RPA application with the understanding that if both applications are judged to be meritorious and considered for funding, only one of the awards could be accepted

• To prevent a lapse in funding, current NINDS R35 grantees can submit a new NINDS Type 1 R35 application in years 7-8 of their active R35 award. PD/PIs can submit other overlapping applications (e.g., R01s) during this period. However, if all applications receive fundable scores, PD/PIs will have to choose between either the new R35 or one or more of the other non-R35 NINDS awards.
• If the PD/PI of an active NINDS R35 award submits a new NINDS Type 1 R35 application prior to the 7^th year of their active R35 and receives a fundable score, the remaining time and funds from the active NINDS R35 must be relinquished if the PD/PI chooses to accept the new award.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Alisa Schaefer, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
E-mail: alisa.schaefer@nih.gov